Eom Bang Wool, Won Ryu Keun, Man Yoon Hong, Kook Myeong-Cherl
Center for Gastric Cancer, National Cancer Center, Goyang-si 10408, Republic of Korea.
Chin J Cancer Res. 2020 Oct 31;32(5):614-620. doi: 10.21147/j.issn.1000-9604.2020.05.06.
There has been a demand for a tumor-specific marker for metastatic lymph nodes in sentinel navigation surgery for gastric cancer. The aim of this study is to analyze protein expression in both primary tumors and metastatic lymph nodes in early gastric cancer patients.
We collected primary tumors and metastatic lymph nodes from 71 patients who underwent curative gastrectomy and pathologically diagnosed with T1N1 or T1N2 (8th Union for International Cancer Control 8th edition/American Joint Committee on Cancer staging system) gastric cancer. Immunohistochemistry was used to determine the expression of six cell membrane proteins, including carcinoembryonic antigen (CEA), E-cadherin, epithelial cell adhesion molecule (EpCAM), P-cadherin, CD44v6, and c-erbB2 in the patient samples.
The expression of CEA, E-cadherin, EpCAM, P-cadherin, CD44v6 and c-erbB2 in the evaluable primary tumor samples was 75.4%, 97.1%, 100%, 89.9%, 11.1% and 7.2%, respectively. Among cases wherein both the primary tumor and metastatic lymph nodes were evaluable, double positivity (expression in both primary tumor and metastatic lymph nodes) was observed for CEA, E-cadherin, EpCAM, P-cadherin, CD44v6 and c-erbB2 in 53.2%, 97.9%, 98.1%, 76.6%, 0 and 6.8% of the cases, respectively. The proportion of metastatic lymph nodes positive for CEA, E-cadherin, EpCAM, P-cadherin, CD44v6 and c-erbB2 was 71.4%, 100%, 98.1%, 83.7%, 0, and 75%, respectively in primary tumors positive for the same markers.
E-cadherin and EpCAM had an overlap of 100% and 98.1% between the primary tumor and metastatic lymph nodes, respectively. Thus, E-cadherin and EpCAM are potential molecular markers to detect metastatic lymph nodes in patients with early gastric cancer.
在胃癌前哨导航手术中,对转移性淋巴结的肿瘤特异性标志物存在需求。本研究的目的是分析早期胃癌患者原发肿瘤和转移性淋巴结中的蛋白质表达。
我们收集了71例行根治性胃切除术且经病理诊断为T1N1或T1N2(国际癌症控制联盟第8版/美国癌症联合委员会分期系统)胃癌患者的原发肿瘤和转移性淋巴结。采用免疫组织化学法测定患者样本中六种细胞膜蛋白的表达,包括癌胚抗原(CEA)、E-钙黏蛋白、上皮细胞黏附分子(EpCAM)、P-钙黏蛋白、CD44v6和c-erbB2。
在可评估的原发肿瘤样本中,CEA、E-钙黏蛋白、EpCAM、P-钙黏蛋白、CD44v6和c-erbB2的表达分别为75.4%、97.1%、100%、89.9%、11.1%和7.2%。在原发肿瘤和转移性淋巴结均可评估的病例中,CEA、E-钙黏蛋白、EpCAM、P-钙黏蛋白、CD44v6和c-erbB2的双阳性(原发肿瘤和转移性淋巴结中均表达)分别见于53.2%、97.9%、98.1%、76.6%、0和6.8%的病例。在相同标志物阳性的原发肿瘤中,CEA、E-钙黏蛋白、EpCAM、P-钙黏蛋白、CD44v6和c-erbB2在转移性淋巴结中的阳性比例分别为71.4%、100%、98.1%、83.7%、0和75%。
E-钙黏蛋白和EpCAM在原发肿瘤和转移性淋巴结之间的重叠率分别为100%和98.1%。因此,E-钙黏蛋白和EpCAM是检测早期胃癌患者转移性淋巴结的潜在分子标志物。